ArticleAnnals of surgical oncology2026

Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.

Akira Hamada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.